Equity research analysts covering Codexis, Inc. (CDXS) maintain twelve-month consensus price targets that reflect cautious optimism regarding its proprietary enzyme engineering platforms and commercial partnerships. While individual institutional forecasts vary based on clinical-stage biotechnology valuation models and projected revenue scaling from its ECO Synthesis platform, analysts regularly update these targets following quarterly earnings disclosures. Investors tracking consensus estimates should review live financial market terminals to evaluate current analyst sentiment and target ranges.